Matthew Lelegren
First author of a 2016 study of how rapamycin changes the protein-quality-control machinery in marmoset liver, muscle and fat, carried out in Adam Salmon's group in San Antonio
Geriatric Research, Education and Clinical Center, South Texas Veterans Health Care System, and Barshop Institute, UT Health San Antonio (at the time of the study, 2016)
Cells keep their proteins in good shape with a set of systems called the proteostasis network. Proteasomes chop up damaged proteins, chaperones help proteins fold, and autophagy recycles larger pieces of the cell. Blocking mTOR is thought to boost some of these systems, which may be part of how rapamycin slows aging in mice.
Matthew Lelegren was first author of the 2016 Atlas study (LEL2016) that checked this idea in a primate, using tissue from common marmosets treated with rapamycin in an earlier pilot. In liver and muscle, rapamycin went with more of PSMB5, a core proteasome subunit, but proteasome activity did not change. Chaperones that work inside mitochondria rose in muscle but not liver, and autophagy rose in muscle and fat but not liver. Only parts of the network responded, and differently in each tissue. The samples came from a small group of animals, and the changes are protein levels, not proven effects on health.
The work was done at the South Texas Veterans Health Care System and the Barshop Institute in San Antonio, with Adam Salmon as senior author. No later research paper tied to this person could be confirmed, so the current position is not known.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2016 | A | Pharmaceutical inhibition of mTOR in the common marmoset: effect of rapamycin on regulators of proteostasis in a non-human primate. LEL2016 First author: measured proteasome, chaperone and autophagy markers in rapamycin-treated marmoset tissues and found tissue-specific changes. |
Co-authors in the Atlas 3
People with a profile here who share at least one study with Matthew Lelegren.
ShowHide
- Adam B. Salmon Biologist of aging at UT Health San Antonio whose work in this Atlas spans rapamycin in mice and in common marmosets. He is a co-author on the Interventions Testing Program reports from the San Antonio site and on the marmoset rapamycin studies on blood markers, epigenetic age and the salivary gland
- Corinna Ross Primate biologist at Texas Biomedical Research Institute who uses the common marmoset to test whether drugs such as rapamycin can protect health during aging
- Suzette Tardif Primate biologist who spent more than 30 years developing the common marmoset as a research model, and who led the first studies of rapamycin dosing and safety in this small monkey
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.